Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results Meeting Abstract
| Authors: | Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fahkri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T. S.; Coombs, C. C.; Flinn, I.; Lewis, D. J.; Le Gouill, S.; Palomba, M. L.; Woyach, J. A.; Pagel, J. M.; Lamanna, N.; Barve, M. A.; Ghia, P.; Eyre, T. A.; Yin, M.; Nair, B.; Tsai, D. E.; Ku, N. C.; Mato, A. R.; Cheah, C. Y.; Wang, M. L. |
| Abstract Title: | Pirtobrutinib (LOXO-305), a next-generation, highly selective, non-covalent Bruton's tyrosine kinase inhibitor in previously treated mantle cell lymphoma and other non-Hodgkin lymphomas: Phase 1/2 BRUIN study results |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | nhl; btk inhibitor; mcl; abcl; bruin; non-covalent |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S378 |
| End Page: | S379 |
| Language: | English |
| ACCESSION: | WOS:000691910500301 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01863-2 |
| Notes: | Meeting Abstract: ABCL-040 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work